Development of pneumococcal vaccines over the last 10 years

Nicola Principi, Susanna Esposito

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Introduction: Although significant improvements in the prevention of pneumococcal infections have been achieved in recent years, Streptococcus pneumoniae remains a leading cause of morbidity and mortality. To prevent S. pneumoniae infections, vaccines have been developed for several years. Areas covered: In this review, the most important emerging problems regarding pneumococcal conjugate vaccines (PCVs) are discussed in addition to the status of new vaccine design and development. Given the medical, social and economic relevance of pneumococcal diseases, the availability of effective and safe vaccines against S. pneumoniae is a key objective of public health. Expert opinion: Protein vaccines using agents different from capsular polysaccharides (CPs) or whole-cell vaccines seem to induce a broader immune response than PCVs and theoretically offer definitive solutions, as they can stimulate both humoral and cellular immunity. Moreover, these vaccines, particularly the whole-cell vaccine, are simpler to produce and significantly less expensive. However, the development of these preparations is very far from completion. It is highly likely that for a long time, no new safe and effective pneumococcal vaccines will be available. The best formulation of new pneumococcal vaccines has not been established. Consequently, an effort towards the expanded use of the available vaccines has to be made.

Original languageEnglish
Pages (from-to)7-17
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2 2018

Fingerprint

Pneumococcal Vaccines
Vaccines
Pneumococcal Infections
Conjugate Vaccines
Streptococcus pneumoniae
Medical Economics
Expert Testimony
Public health
Humoral Immunity
Cellular Immunity
Polysaccharides
Public Health
Availability
Morbidity
Economics
Mortality

Keywords

  • Invasive pneumococcal disease
  • non-invasive pneumococcal disease
  • pneumococcal conjugate vaccine
  • pneumococcal protein vaccine
  • pneumococcal vaccines
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Development of pneumococcal vaccines over the last 10 years. / Principi, Nicola; Esposito, Susanna.

In: Expert Opinion on Biological Therapy, Vol. 18, No. 1, 02.01.2018, p. 7-17.

Research output: Contribution to journalReview article

Principi, Nicola ; Esposito, Susanna. / Development of pneumococcal vaccines over the last 10 years. In: Expert Opinion on Biological Therapy. 2018 ; Vol. 18, No. 1. pp. 7-17.
@article{974e0fc6f44f49009a8e49e57ce0481f,
title = "Development of pneumococcal vaccines over the last 10 years",
abstract = "Introduction: Although significant improvements in the prevention of pneumococcal infections have been achieved in recent years, Streptococcus pneumoniae remains a leading cause of morbidity and mortality. To prevent S. pneumoniae infections, vaccines have been developed for several years. Areas covered: In this review, the most important emerging problems regarding pneumococcal conjugate vaccines (PCVs) are discussed in addition to the status of new vaccine design and development. Given the medical, social and economic relevance of pneumococcal diseases, the availability of effective and safe vaccines against S. pneumoniae is a key objective of public health. Expert opinion: Protein vaccines using agents different from capsular polysaccharides (CPs) or whole-cell vaccines seem to induce a broader immune response than PCVs and theoretically offer definitive solutions, as they can stimulate both humoral and cellular immunity. Moreover, these vaccines, particularly the whole-cell vaccine, are simpler to produce and significantly less expensive. However, the development of these preparations is very far from completion. It is highly likely that for a long time, no new safe and effective pneumococcal vaccines will be available. The best formulation of new pneumococcal vaccines has not been established. Consequently, an effort towards the expanded use of the available vaccines has to be made.",
keywords = "Invasive pneumococcal disease, non-invasive pneumococcal disease, pneumococcal conjugate vaccine, pneumococcal protein vaccine, pneumococcal vaccines, Streptococcus pneumoniae",
author = "Nicola Principi and Susanna Esposito",
year = "2018",
month = "1",
day = "2",
doi = "10.1080/14712598.2018.1384462",
language = "English",
volume = "18",
pages = "7--17",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Development of pneumococcal vaccines over the last 10 years

AU - Principi, Nicola

AU - Esposito, Susanna

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Introduction: Although significant improvements in the prevention of pneumococcal infections have been achieved in recent years, Streptococcus pneumoniae remains a leading cause of morbidity and mortality. To prevent S. pneumoniae infections, vaccines have been developed for several years. Areas covered: In this review, the most important emerging problems regarding pneumococcal conjugate vaccines (PCVs) are discussed in addition to the status of new vaccine design and development. Given the medical, social and economic relevance of pneumococcal diseases, the availability of effective and safe vaccines against S. pneumoniae is a key objective of public health. Expert opinion: Protein vaccines using agents different from capsular polysaccharides (CPs) or whole-cell vaccines seem to induce a broader immune response than PCVs and theoretically offer definitive solutions, as they can stimulate both humoral and cellular immunity. Moreover, these vaccines, particularly the whole-cell vaccine, are simpler to produce and significantly less expensive. However, the development of these preparations is very far from completion. It is highly likely that for a long time, no new safe and effective pneumococcal vaccines will be available. The best formulation of new pneumococcal vaccines has not been established. Consequently, an effort towards the expanded use of the available vaccines has to be made.

AB - Introduction: Although significant improvements in the prevention of pneumococcal infections have been achieved in recent years, Streptococcus pneumoniae remains a leading cause of morbidity and mortality. To prevent S. pneumoniae infections, vaccines have been developed for several years. Areas covered: In this review, the most important emerging problems regarding pneumococcal conjugate vaccines (PCVs) are discussed in addition to the status of new vaccine design and development. Given the medical, social and economic relevance of pneumococcal diseases, the availability of effective and safe vaccines against S. pneumoniae is a key objective of public health. Expert opinion: Protein vaccines using agents different from capsular polysaccharides (CPs) or whole-cell vaccines seem to induce a broader immune response than PCVs and theoretically offer definitive solutions, as they can stimulate both humoral and cellular immunity. Moreover, these vaccines, particularly the whole-cell vaccine, are simpler to produce and significantly less expensive. However, the development of these preparations is very far from completion. It is highly likely that for a long time, no new safe and effective pneumococcal vaccines will be available. The best formulation of new pneumococcal vaccines has not been established. Consequently, an effort towards the expanded use of the available vaccines has to be made.

KW - Invasive pneumococcal disease

KW - non-invasive pneumococcal disease

KW - pneumococcal conjugate vaccine

KW - pneumococcal protein vaccine

KW - pneumococcal vaccines

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=85038422748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038422748&partnerID=8YFLogxK

U2 - 10.1080/14712598.2018.1384462

DO - 10.1080/14712598.2018.1384462

M3 - Review article

VL - 18

SP - 7

EP - 17

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 1

ER -